John J P Kastelein Selected Research

Lipoproteins (Lipoprotein)

1/2019	Mendelian Randomization Study of ACLY and Cardiovascular Disease.
1/2019	Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
11/2018	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.
10/2017	Effects of Supra-Physiological Levothyroxine Dosages on Liver Parameters, Lipids and Lipoproteins in Healthy Volunteers: A Randomized Controlled Crossover Study.
1/2017	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
1/2017	Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report.
7/2016	Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia.
2/2016	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.
12/2015	What does the future hold for cholesteryl ester transfer protein inhibition?
10/2014	Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John J P Kastelein Research Topics

Disease

122	Cardiovascular Diseases (Cardiovascular Disease) 11/2022 - 01/2002
107	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022 - 07/2002
76	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 05/2002
75	Atherosclerosis 01/2021 - 01/2002
62	Coronary Disease (Coronary Heart Disease) 01/2019 - 04/2002
40	Myocardial Infarction 01/2021 - 12/2002
24	Inflammation (Inflammations) 04/2022 - 12/2002
22	Hypercholesterolemia 09/2020 - 10/2003
21	Stroke (Strokes) 01/2019 - 04/2005
20	Dyslipidemias (Dyslipidemia) 12/2020 - 10/2004
17	Atherosclerotic Plaque (Atheroma) 01/2021 - 02/2006
17	Hypertension (High Blood Pressure) 07/2018 - 06/2004
13	Neoplasms (Cancer) 01/2019 - 09/2004
12	Homozygous Familial Hypercholesterolemia 05/2022 - 03/2014
12	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2013 - 04/2005
11	Injection Site Reaction 09/2020 - 08/2007
11	Vascular Diseases (Vascular Disease) 11/2016 - 12/2002
10	Hypertriglyceridemia 01/2022 - 09/2004
10	Hyperlipidemias (Hyperlipidemia) 01/2022 - 02/2002
10	Type 2 Diabetes Mellitus (MODY) 05/2021 - 12/2004
10	Acute Coronary Syndrome 01/2019 - 04/2005
10	Diabetes Mellitus 01/2018 - 11/2005
10	Carotid Artery Diseases 12/2013 - 05/2003
9	Unstable Angina 01/2019 - 11/2008
8	Insulin Resistance 11/2022 - 07/2007
7	Hypoalphalipoproteinemias (Hypoalphalipoproteinemia) 12/2014 - 10/2002
6	Body Weight (Weight, Body) 01/2020 - 05/2007
6	Inborn Genetic Diseases (Disease, Hereditary) 01/2019 - 04/2005
6	Heart Failure 12/2015 - 02/2007
5	Pancreatitis 12/2019 - 09/2004
5	Hypotension (Low Blood Pressure) 11/2016 - 04/2005
5	Abdominal Obesity 07/2011 - 01/2008
4	Chronic Renal Insufficiency 01/2019 - 12/2006
4	Infections 01/2017 - 10/2004
4	Heart Arrest (Cardiac Arrest) 04/2012 - 04/2005

Drug/Important Bio-Agent (IBA)

122	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 07/2002
98	LDL CholesterolIBA 11/2022 - 04/2002
91	LipidsIBA 04/2022 - 10/2002
75	oxidized low density lipoproteinIBA 11/2022 - 04/2002
65	HDL CholesterolIBA 11/2022 - 05/2002
46	CholesterolIBA 01/2022 - 01/2002
36	Lipoproteins (Lipoprotein)IBA 01/2019 - 08/2002
35	Atorvastatin (Lipitor)FDA Link 01/2019 - 12/2002
28	Triglycerides (Triacylglycerol)IBA 01/2019 - 06/2004
28	ApolipoproteinsIBA 03/2018 - 06/2003
27	Apolipoproteins B (ApoB)IBA 11/2022 - 10/2003
25	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020 - 10/2003
24	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2021 - 10/2004
24	Biomarkers (Surrogate Marker)IBA 01/2016 - 12/2002
23	Simvastatin (Zocor)FDA LinkGeneric 03/2013 - 07/2002
22	C-Reactive ProteinIBA 01/2019 - 12/2002
19	HDL LipoproteinsIBA 01/2018 - 08/2004
18	Cholesterol Ester Transfer ProteinsIBA 09/2022 - 01/2003
18	LDL Receptors (LDL Receptor)IBA 01/2019 - 12/2002
15	Pravastatin (Pravachol)FDA LinkGeneric 10/2019 - 05/2003
12	Ezetimibe (Zetia)FDA Link 01/2021 - 02/2005
12	alirocumabIBA 09/2020 - 06/2014
12	Rosuvastatin Calcium (Crestor)FDA Link 01/2018 - 03/2003
12	Trinitrotoluene (TNT)IBA 11/2016 - 09/2006
11	Proprotein Convertase 9IBA 01/2021 - 06/2014
9	mipomersenIBA 01/2021 - 05/2010
9	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2019 - 09/2004
8	Glucose (Dextrose)FDA LinkGeneric 11/2022 - 06/2004
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2003
7	Pharmaceutical PreparationsIBA 01/2020 - 02/2004
7	torcetrapibIBA 11/2012 - 04/2007
6	EnzymesIBA 04/2022 - 06/2006
6	dalcetrapibIBA 12/2014 - 05/2002
5	Insulin (Novolin)FDA Link 09/2022 - 09/2009
5	Lipoprotein(a)IBA 01/2022 - 06/2004
5	DNA (Deoxyribonucleic Acid)IBA 08/2017 - 05/2004
5	Secretory Phospholipases A2IBA 01/2014 - 04/2005
5	AdiponectinIBA 01/2012 - 01/2008
5	Adenosine Triphosphate (ATP)IBA 10/2011 - 10/2002
4	ALN-PCSIBA 01/2021 - 01/2017
4	CSL112IBA 01/2021 - 10/2016
4	evolocumabIBA 10/2020 - 06/2016
4	Monoclonal AntibodiesIBA 01/2020 - 06/2014
4	bococizumabIBA 07/2018 - 08/2016
4	CER-001IBA 01/2018 - 12/2014
4	lipoprotein cholesterolIBA 11/2016 - 04/2005
4	Phytosterols (Plant Sterols)IBA 12/2014 - 12/2005
4	Aryldialkylphosphatase (Paraoxonase)IBA 08/2009 - 02/2005
3	Eicosapentaenoic AcidIBA 04/2022 - 01/2014
3	Fatty Acids (Saturated Fatty Acids)IBA 04/2022 - 01/2016
3	icosabutateIBA 04/2022 - 01/2016
3	Nonesterified Fatty Acids (NEFA)IBA 01/2022 - 01/2012
3	BMS201038IBA 01/2021 - 03/2014
3	Phospholipids (Phosphatides)FDA LinkGeneric 11/2020 - 05/2006
3	CreatinineIBA 01/2019 - 12/2006
3	omega-Chloroacetophenone (Mace)IBA 01/2019 - 12/2015
3	varespladibIBA 01/2019 - 04/2011
3	Apolipoprotein C-IIIIBA 11/2018 - 07/2015

Therapy/Procedure

94	Therapeutics 09/2022 - 08/2002
10	Secondary Prevention 01/2021 - 11/2005
5	Resuscitation 06/2013 - 04/2005
4	Drug Therapy (Chemotherapy) 01/2021 - 06/2004
4	Subcutaneous Injections 01/2021 - 12/2016
3	Blood Component Removal (Apheresis) 01/2021 - 10/2014
3	Intravenous Infusions 01/2020 - 01/2018